SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW.
Yang M, et al. Among authors: lee gs.
J Clin Oncol. 2011 Jun 20;29(18):2565-73. doi: 10.1200/JCO.2010.31.2405. Epub 2011 May 23.
J Clin Oncol. 2011.
PMID: 21606417
Free PMC article.